Janakiraman Subramanian, MD
Medical Oncology · Fairfax, VANPI 1366589343
Payments from drug & device makers
Across 708 payments — averaging $2717.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$551K
- AstraZeneca$234K
- Tesaro, Inc.$173K
- GSK$132K
- Incyte Corporation$131K
- Novartis$121K
- plus $582K from 27 others
Across 2 payments — averaging $6801.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$13K
- F. Hoffmann-la Roche AG$478
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 160 | $550,830 |
| AstraZeneca | 140 | $234,431 |
| Tesaro, Inc. | 19 | $173,429 |
| GSK | 27 | $131,608 |
| Incyte Corporation | 50 | $130,587 |
| Novartis | 9 | $121,090 |
| Genentech, Inc. | 31 | $111,008 |
| Jazz Pharmaceuticals Inc. | 62 | $109,605 |
| Johnson & Johnson | 66 | $64,837 |
| Exelixis Inc. | 25 | $52,001 |
| Novocure Inc. | 10 | $39,045 |
| Boehringer Ingelheim | 12 | $38,797 |
| Amgen | 10 | $29,215 |
| Helsinn Healthcare SA | 5 | $29,050 |
| AbbVie | 3 | $23,900 |
| Daiichi Sankyo Inc. | 19 | $19,387 |
| F. Hoffmann-la Roche AG | 11 | $15,954 |
| EMD Serono, Inc. | 2 | $12,220 |
| Sanofi | 14 | $9,536 |
| Lilly USA, LLC | 10 | $8,318 |
| Pfizer | 2 | $4,405 |
| Daiichi Sankyo Europe GmbH | 3 | $3,990 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $3,038 |
| Beigene, Ltd. | 1 | $1,950 |
| Blueprint Medicines Corporation | 1 | $1,540 |
| Bayer | 1 | $1,140 |
| Genentech USA, Inc. | 1 | $1,070 |
| Janssen Scientific Affairs, LLC | 1 | $1,010 |
| G1 Therapeutics, Inc. | 1 | $750 |
| Coherus Oncology, Inc. | 2 | $260 |
| Janssen Global Services, LLC | 1 | $87 |
| Regeneron Healthcare Solutions, Inc. | 2 | $65 |
| Gilead | 1 | $12 |
How this compares
$1,924,164 in reported general payments places this provider in the 90th percentile of 95 medical oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Fairfax
- Alexander SpiraFairfax$69.5M
- Kathleen HarndenFairfax$4M
- Adam CohenFairfax$2.2M
- Timothy CannonFairfax$1.9M
- Anne FavretFairfax$1.9M
- John DeekenFairfax$1.6M
- Arthur WinerFairfax$923K
- Nagla Abdel KarimFairfax$911K
- Amin BenyounesFairfax$824K
- Eun-Mi YuFairfax$529K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.